Medicinal Cannabis in Insurance Claims: TGA Regulation and Clinical Review
Understanding medicinal cannabis pathways, evidence base, TGA approval, safety considerations, and medication review strategy for Australian insurers.
Published: 3 April 2026 | Updated: 3 April 2026
Why Medicinal Cannabis Is Increasingly Relevant in Your Claims
Medicinal cannabis has emerged as an increasingly common request in your insurance claims portfolio, particularly for chronic pain, neuropathic pain, and spasticity. Since Australia's Therapeutic Goods Administration (TGA) legalised medicinal cannabis in 2016, patient demand and practitioner familiarity have grown substantially. However, the evidence base remains limited and fragmented; many claims involve "off-label" cannabis use for indications without robust clinical trial data.
As an insurer, your strategic challenge is clarity: distinguishing evidence-supported medicinal cannabis use from experimental or speculative treatment. This article equips you with practical knowledge of TGA pathways, evidence for specific indications, safety considerations, and triggers for medication review.
TGA Regulation of Medicinal Cannabis in Australia
In Australia, medicinal cannabis products are regulated by the TGA under two principal pathways. The Serious Adverse Event (SAS-B) pathway allows patients and practitioners to apply for access to cannabis-based products that are not registered medicines; this pathway is intended for patients who have exhausted conventional therapy. The registered medicine pathway applies to cannabis products that have undergone formal TGA approval, currently a small number of products with defined cannabinoid ratios, standardised dosing, and clinical evidence.
Most medicinal cannabis use in Australian claims operates under SAS-B designation, meaning the product lacks formal regulatory approval. This regulatory status creates clinical and legal ambiguity for insurers. A medication that lacks TGA approval but is legally prescribed under SAS-B creates uncertainty about evidence base, quality control, and your liability for funding experimental therapy.
Cannabinoid Pharmacology and Mechanism
Medicinal cannabis products typically contain cannabidiol (CBD) and tetrahydrocannabinol (THC) in varying ratios. CBD is non-intoxicating and has potential analgesic, anti-inflammatory, and anxiolytic properties. THC is psychoactive and has analgesic and anti-spasticity properties but carries cognitive and dependence risks.
The ratio of CBD to THC is critical. High-CBD, low-THC products minimise intoxication and dependence risk; equal CBD:THC products create more pronounced psychoactive effects and greater abuse potential. In your claims, understand whether the prescribed product is high-CBD (lower risk profile) or balanced CBD:THC (higher intoxication and dependence risk).
Evidence Base for Specific Indications
Evidence for medicinal cannabis varies substantially across indications. Strongest evidence exists for cannabis-derived cannabinoids in chemotherapy-induced nausea, multiple sclerosis spasticity, and chronic pain in specific populations. Moderate evidence supports use in neuropathic pain and intractable epilepsy. Weak evidence supports use in anxiety, insomnia, or generalised chronic pain without specific indication.
In your claims, scrutinise the indication: is it evidence-supported, or is it speculative? A claimant with multiple sclerosis spasticity using high-CBD cannabis has reasonable evidence basis. A claimant with general musculoskeletal pain using balanced CBD:THC cannabis lacks strong evidence support and warrants clinical questioning.
| Indication | Evidence Strength | Appropriate Pathway in Claims | Medication Review Trigger |
|---|---|---|---|
| Multiple sclerosis spasticity | Strong (Sativex approved) | Registered medicine preferred; SAS-B acceptable if Sativex unavailable | Efficacy plateau beyond 12 weeks; dose escalation without improvement |
| Chemotherapy-induced nausea | Moderate-Strong | SAS-B with documented trial of conventional agents first | Any escalation beyond initial effective dose; alternative agents available |
| Neuropathic pain (specific type) | Moderate | SAS-B after trial of evidence-based agents (gabapentin, pregabalin, duloxetine) | Documentation of prior trials; efficacy plateau; THC content assessment |
| Chronic pain (generalised) | Weak | Not recommended in claims; consider conventional agents first | Immediate review; reassess indication and prior therapy trials |
| Anxiety or insomnia | Weak (THC risk concerns) | Not recommended; consider SSRIs for anxiety, CBT-I for insomnia | Immediate review; assess alternative evidence-based options |
Safety Considerations and Adverse Effects
Medicinal cannabis, particularly THC-containing products, carries several safety concerns relevant to your claims. THC impairs cognition, motor coordination, and reaction time, affecting return-to-work capacity. Regular use can trigger or exacerbate anxiety, paranoia, or psychosis, particularly in claimants with personal or family history of mental illness. Cannabis can increase heart rate and blood pressure, creating risk in claimants with pre-existing cardiovascular disease.
Cannabis is also associated with cannabis hyperemesis syndrome in some chronic users, characterised by nausea and vomiting that paradoxically improves with cannabis cessation. Additionally, chronic cannabis use has been associated with amotivational syndrome, characterised by apathy and reduced motivation, potentially impairing return-to-work recovery.
Dependence and Withdrawal Risks
Regular cannabis use, particularly high-THC products, can lead to psychological and physical dependence. Cannabis withdrawal is not life-threatening like benzodiazepine withdrawal, but it's clinically significant: irritability, sleep disturbance, anxiety, and reduced appetite typically emerge within 1 to 2 weeks of cessation and can persist for 2 to 4 weeks. For your claims, this means cannabis cessation, if needed, requires structured support and claimant education about withdrawal expectations.
When to Refer for a Medication Review
Medicinal cannabis use in your claims warrants medication review in several scenarios:
- Initial medicinal cannabis prescription; assess indication appropriateness against evidence base and trial of conventional agents.
- SAS-B designation; clarify whether conventional evidence-based agents have been tried; understand reason for SAS-B pathway selection.
- Use beyond 12 weeks without documented efficacy assessment; clarify whether cannabis is materially improving functional outcomes.
- Dose escalation without documented clinical justification; assess whether tolerance developing.
- Any concurrent use of THC-containing cannabis with opioids; additive CNS depression risk.
- Claimant reports anxiety, paranoia, or mood changes potentially attributable to cannabis.
- Return-to-work milestone approaching; assess whether cannabis affects work capacity or safety.
- Any indication outside strong evidence window (anxiety, insomnia, generalised pain); immediate review warranted.
Medication Review Workflow: Medicinal Cannabis
Step 1: Indication Verification Pharmacist confirms diagnosis, indication appropriateness against evidence base, and documentation of conventional therapy trials.
Step 2: Product Assessment Assess product type, CBD:THC ratio, dose, and whether ratio aligns with indication (high-CBD preferred unless low-THC contraindicated).
Step 3: Efficacy Documentation Evaluate whether cannabis is delivering measurable functional improvement in pain, spasticity, or target symptom; determine whether improvement justifies ongoing cost and safety risk.
Step 4: Safety Screening Assess for cognitive impairment, mood changes, cardiovascular symptoms, or signs of cannabis hyperemesis syndrome attributable to cannabis use.
Step 5: Return-to-Work Assessment Determine whether cannabis use affects work capacity, safety sensitivity, or driving safety; assess cessation feasibility if needed for work return.
Medicinal Cannabis and Return-to-Work
Cannabis, particularly THC-containing products, impairs cognitive function, reaction time, and motor coordination. For claimants approaching return-to-work, particularly in safety-sensitive occupations, cannabis use may constitute a barrier to work readiness. A medication review focused on return-to-work can assess whether cannabis optimisation (dose reduction, switch to higher-CBD product) or cessation is necessary to support safe work return.
Additionally, some employers have strict drug-testing policies that flag cannabis metabolites, potentially preventing work return even if functional impairment is minimal. A medication review will clarify these workplace considerations with the claimant and their employer.
Cannabis and Poly-Pharmacy Considerations
Cannabis combined with opioids amplifies CNS depression and respiratory depression risk. Combined use with alcohol similarly increases CNS depression and overdose risk. In your claims, any claimant on medicinal cannabis with concurrent opioid or significant alcohol use warrants immediate medication review and likely cannabis cessation or opioid reduction.
Cost and Accessibility in Your Claims
Medicinal cannabis products under SAS-B designation are not listed on the Pharmaceutical Benefits Scheme (PBS) and are not covered by standard insurance medication benefits in Australia. Cost is typically borne by claimant or insurer as an out-of-pocket expense. For your organisation, this means funding medicinal cannabis represents a direct cost decision; this warrants additional scrutiny to ensure indication is evidence-supported and conventional alternatives have been exhausted.
Summary and Key Takeaways
Medicinal cannabis in your claims represents an emerging therapeutic option with limited evidence base that demands careful clinical scrutiny:
- Most medicinal cannabis in Australian claims is SAS-B designated, meaning it lacks formal TGA approval; stronger evidence base preferred.
- Evidence is strongest for multiple sclerosis spasticity and chemotherapy-induced nausea; moderate for neuropathic pain; weak for anxiety, insomnia, or generalised pain.
- THC-containing products carry cognitive impairment, mood effects, and dependence risks; high-CBD products lower risk.
- Cannabis use beyond 12 weeks should be supported by documented efficacy; absence of measurable functional improvement warrants cessation.
- Return-to-work implications require explicit assessment; cannabis impairs cognition and safety-sensitive work capacity.
- A pharmacist-led medication review of medicinal cannabis assesses indication appropriateness, product selection, efficacy, and safety, supporting informed insurer decision-making.
Are you funding medicinal cannabis appropriately in your claims?
IMM's medication review specialists assess medicinal cannabis use for indication appropriateness, evidence base, product selection, and safety. We help clarify whether cannabis represents justified therapy or whether evidence-based conventional alternatives remain appropriate, enabling informed insurer decisions that protect both claimant welfare and organisational risk management.
Request a Medication Review
